Aquestive Therapeutics (AQST) Scheduled to Post Quarterly Earnings on Tuesday

Aquestive Therapeutics (NASDAQ:AQST – Get Rating) is set to announce its earnings results after the market closes on Tuesday, May 3rd. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Aquestive Therapeutics has set its FY 2022 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Aquestive Therapeutics (NASDAQ:AQST – Get Rating) last released its earnings results on Tuesday, March 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The company had revenue of $11.08 million for the quarter, compared to analyst estimates of $9.81 million. During the same period in the prior year, the business posted ($0.60) earnings per share. On average, analysts expect Aquestive Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aquestive Therapeutics stock opened at $1.91 on Tuesday. The company has a market cap of $79.20 million, a P/E ratio of -1.04 and a beta of 3.30. Aquestive Therapeutics has a 1-year low of $1.89 and a 1-year high of $6.40. The company has a fifty day simple moving average of $2.53 and a 200 day simple moving average of $3.77.

AQST has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, April 20th. Wedbush decreased their target price on shares of Aquestive Therapeutics from $26.00 to $8.00 and set an “outperform” rating for the company in a research report on Thursday, March 10th.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Aquestive Therapeutics by 5.3% in the 4th quarter. BlackRock Inc. now owns 348,366 shares of the company’s stock valued at $1,354,000 after acquiring an additional 17,420 shares during the period. Virtu Financial LLC bought a new position in shares of Aquestive Therapeutics in the 4th quarter valued at about $308,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Aquestive Therapeutics in the 4th quarter valued at about $411,000. Millennium Management LLC lifted its stake in shares of Aquestive Therapeutics by 10.8% during the 4th quarter. Millennium Management LLC now owns 358,875 shares of the company’s stock worth $1,396,000 after buying an additional 35,101 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Aquestive Therapeutics during the 4th quarter worth about $116,000. 39.17% of the stock is owned by institutional investors.

About Aquestive Therapeutics (Get Rating)

Aquestive Therapeutics, Inc, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

See Also